Explore 3 Stock Ideas & Industry Insights Download Free Report

News

e.l.f. Beauty (NYSE: ELF) Expands Retail Reach in The Netherlands and Belgium Through Kruidvat and Trekpleister

e.l.f. Beauty has announced a retail expansion in the Netherlands and Belgium through partnerships with two major drugstore chains, Kruidvat and Trekpleister. Starting May 26, 2025, consumers in both countries will be able to find e.l.f. Cosmetics and e.l.f. SKIN products on shelves in …

Team Kalkine | 15 May 2025

VEON (Nasdaq: VEON) Reports 1Q2025 Earnings with 50% Digital Revenue Growth and Higher EBITDA

VEON Ltd. (Nasdaq: VEON) has reported its financial and operational performance for the first quarter of 2025, showing revenue and earnings growth alongside expanding digital revenues. The company generated $1.03 billion in revenue, reflecting an 8.9% year-on-year increase in U.S. dollar terms. In local …

Team Kalkine | 15 May 2025

Cancun and Las Vegas Emerge as Top Picks in Tripadvisor's 2025 Summer Travel Index

Tripadvisor has released its 2025 Summer Travel Index, offering a detailed look into how U.S. travelers are preparing for the upcoming vacation season. The data, based on both site analytics and a global survey, suggests a busy summer ahead with 63% of respondents expressing …

Team Kalkine | 15 May 2025

Stardust Power (Nasdaq: SDST) Reports Q1 2025 Financial Results Amid Progress on Muskogee Lithium Facility

Stardust Power Inc. (Nasdaq: SDST), a U.S.-based developer of battery-grade lithium products, released its financial results for the first quarter of 2025, reporting ongoing development activity at its planned Muskogee refinery site and continued investment in early-stage operations.

Team Kalkine | 15 May 2025

AbCellera (Nasdaq: ABCL) Receives Clearance to Begin Phase 1 Trial of ABCL635 for Menopausal Hot Flashes

AbCellera Biologics Inc. (Nasdaq: ABCL) has received a No Objection Letter (NOL) from Health Canada, authorizing the company to proceed with a Phase 1 clinical trial for its investigational drug candidate ABCL635. The study is focused on addressing moderate-to-severe vasomotor symptoms (VMS), commonly referred …

Team Kalkine | 15 May 2025

Daily Market Brief: Stocks Gain on Trade Optimism, Commodities Pull Back, Mortgage Rates Inch Higher

Index Update:U.S. stocks were set to open higher, extending recent gains fueled by U.S.-China tariff reductions, though the rally's momentum appeared to be slowing. Futures on major indexes posted modest increases, with the Nasdaq leading. In premarket action, Nvidia rose over 3% on news …

Team Kalkine | 14 May 2025

Telstra, Accenture (NYSE: ACN) Launch AI Innovation Hub in Silicon Valley to Accelerate Data Strategy

Telstra and Accenture (NYSE: ACN) have launched a dedicated AI hub in Silicon Valley, forming the centerpiece of their recently established joint venture. This facility aims to drive Telstra’s enterprise-wide AI transformation over the next seven years, focusing on foundational AI architecture, data strategy …

Team Kalkine | 14 May 2025

Broadridge (NYSE: BR) Secures U.S. Patent for LLM Agent Orchestration Behind BondGPT Platform

Broadridge Financial Solutions Inc. (NYSE: BR) has been granted U.S. Patent No. 11,765,405 for its proprietary methods enabling large language model (LLM) orchestration of machine learning agents, a system powering its BondGPT and BondGPT+ platforms. The patented technology underpins AI tools used on the …

Team Kalkine | 14 May 2025

Google Cloud, Philips Streamline 200K Images Using Vertex AI in New Content Management Overhaul

Google Cloud has partnered with Philips Personal Health Business to overhaul the company’s global content marketing infrastructure using artificial intelligence. Leveraging Google Cloud’s Vertex AI platform, Philips processed more than 200,000 marketing images into 8,000 brand-aligned assets in a matter of hours—a task that …

Team Kalkine | 14 May 2025

Nyxoah (Nasdaq: NYXH) Reports Q1 2025 Revenue of €1.1M, Cash Reserves Decline to €63M

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on treating Obstructive Sleep Apnea (OSA), announced its financial results for the first quarter of 2025, reporting revenue of €1.1 million, down from €1.2 million in the same quarter last year.

Team Kalkine | 14 May 2025